Abre venous self-expanding
stent system
for symptomatic venous outflow obstruction

The Abre™ venous self-expanding stent system is designed for the unique challenges of venous disease. It offers easy deployment, to let physicians focus on their patient, and delivers demonstrated endurance, to give patients freedom of movement.1,2

Contact Us

Overview

Simplicity for you.
Durability for them.

Watch the Abre stent mechanism of action.

Indications

The Abre stent system is intended for use in the iliofemoral veins for the treatment of symptomatic venous outflow obstruction. 

Clinical evidence

The ABRE clinical study demonstrates the safety and effectiveness of the Abre venous stent.1 Learn more about the study and the 24-month results.

  • 88% primary patency at 12 months*
  • 85.7% primary patency at 24 months*
  • 98% freedom from MAEs at 30 days

Product details

Simplicity for you.1,2

Hear it from the expert.

Easy deployment to let you focus on your patient1,2

The Abre stent minimizes jumping and foreshortening, landing precisely where you need it.2

Rotating thumbwheel offers predictable placement and auditory feedback.2

Abre stent and delivery system and zoom on handle with rotating thumbwheel

Triaxial shaft design controls friction and stabilizes stent.2

  1. Isolation sheath
  2. Hemostatic valve
  3. Introducer sheath
  4. Retractable sheath
  5. Inner shaft
Abre system triaxial shaft design zoomed illustration with numbered callouts

Durability for them.1,2

Hear it from the expert.

Demonstrated endurance to give your patients freedom of movement1,2

The nitinol Abre stent maintains lumen integrity and flow in diverse patients and anatomies.1 It ensures radial strength and crush resistance, without compromising flexibility.2

Unique technology:

  • Open-cell design with three offset connection points
  • Struts customized to each size

Consistent behavior across a broad range of diameters and lengths.

Bench evidence shows long-term durability.2 Clinical evidence shows real-world dependability, even in challenging cases.1

  • 0% fracture rate in 50 years in bench testing1
  • 0% fracture rate in clinical trial with 44% of stents extending below inguinal ligament into the CFV‡1
  • 0% migration rate in clinical trial1

  

Model specifications

Product code guide

Abre stent in different sizes and its ordering code components

 Stent diameters

Stent lengths and product numbers 

 

40 mm

60 mm

80 mm

100 mm 

120 mm

150 mm 

10 mm

AB9U10040090

AB9U10060090

AB9U10080090

AB9U10100090

AB9U10120090

AB9U10150090

12 mm

AB9U12060090

AB9U12080090

AB9U12100090

AB9U12120090

AB9U12150090

14 mm

AB9U14060090

AB9U14080090

AB9U14100090

AB9U14120090

AB9U14150090

16 mm

AB9U16060090

AB9U16080090

AB9U16100090

AB9U16120090

AB9U16150090

18 mm

AB9U18060090

AB9U18080090

AB9U18100090

AB9U18120090

AB9U18150090

20 mm

AB9U20060090

AB9U20080090

AB9U20100090

AB9U20120090

AB9U20150090

Additional resources

Contact us

Receive updates and information on our products and therapies.

Review clinical evidence

*

Primary patency was defined as meeting all of the following: freedom from occlusion or restenosis ≥ 50% of the stented segment of the target lesion and freedom from clinically driven target lesion revascularization.

MAEs included all-cause death, clinically significant pulmonary embolism, post-procedural major bleeding complication, stent thrombosis, and stent migration. MAEs were adjudicated by a Clinical Events Committee, except stent thrombosis and stent migration, which were assessed by an imaging core laboratory. 

Site and core lab data were used.

References

1

ABRE CSR v1.2 July 30, 2020 and ABRE 24M PASR v1.0.

2

Test data on file at Medtronic. Report 10558227DOC_Rev A. Bench test results may not be indicative of clinical performance.